ArticleContinence (Amsterdam, Netherlands)2023
Unraveling the complexity of bladder-centric chronic pain by intravesical contrast enhanced MRI.
Article in Continence (Amsterdam, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Why bladder emptying reduces the false-positive results of dynamic renal scintigraphy?International urology and nephrology · 2026Review
- Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration.International journal of molecular sciences · 2024Review
- SWOT and Root Cause Analyses of Antimicrobial Resistance to Oral Antimicrobial Treatment of Cystitis.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Bladder pain, a common symptom associated with various urological conditions, poses a diagnostic challenge as existing imaging modalities fail to pinpoint the bladder as the definitive source of pain. While bladder pain is often linked to localized inflammation resulting from urinary tract infections (UTIs) or Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), which can be exacerbated by emotional stress, current urine-based markers cannot precisely identify the specific site of inflammation within the urinary tract, spanning from the kidneys to the urethral meatus. Cystoscopy, currently considered the gold standard, is recommended by the American Urological Association (AUA) prior to aggressive treatment for IC/BPS patients, as it confirms the presence of bladder inflammation, particularly in Hunner lesions, and predicts a higher response rate to anti-inflammatory medication like cyclosporine. Nonetheless, the invasiveness of cystoscopy, which relies on investigator expertise, coupled with the significant variability in detecting Hunner lesions, underscores its limitations for inflammatory phenotyping. These factors contribute to the reluctance in choosing cystoscopy as a preferred diagnostic method and may also contribute to the lack of success observed in clinical trials assessing the efficacy of novel anti-inflammatory drugs. Given that immune cell infiltration into inflammatory sites relies on tight junction dilatation, the paracellular entry of injected or instilled paramagnetic dyes, mimicking the extravasation of colored dyes such as Evans blue dye could be a robust index of vascular or urothelial hyperpermeability-a characteristic sign of inflammation. This article aims to delve into the pathophysiology of bladder-centric chronic pain within the context of the challenging diagnosis of IC/BPS and explore the pivotal role of Stokesian and Fickian diffusion in the evolution of intravesical contrast-enhanced MRI (ICE-MRI) as a phenotyping tool for bladder pain, transitioning from laboratory research to practical clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.